Aralez Pharmaceuticals Inc (TSX: ARZ), launched in February with a investment led by Deerfield Management, opened the market on April 5th. Aralez, an Ontario domiciled pharmaceutical business focused on developing products for cardiovascular, pain and other specialty areas, emerged from a merger of POZEN Inc and Tribute Pharmaceuticals Canada Inc. The Deerfield-led consortium committed up to US$350 million to the new company.
Aralez Pharmaceuticals Inc. Opens the Market
TORONTO, April 5, 2016 /CNW/ – Adrian Adams, CEO, Aralez Pharmaceuticals Inc. (ARZ), joined Loui Anastasopoulos, Vice President, TSX Company Services, Toronto Stock Exchange & TSX Venture Exchange to open the market.
Headquartered in Ontario, Canada Aralez Pharmaceuticals is a global specialty pharmaceutical focused on the acquisition, development and commercialization of products primarily in cardiovascular, pain and other specialty areas. Aralez Pharmaceuticals Inc. graduated from TSX Venture Exchange and commenced trading on Toronto Stock Exchange on February 9, 2016. Aralez Pharmaceuticals was the second-best performing company in the Clean Technology & Life Sciences sector on the 2016 TSX Venture 50. For more information, please visit www.aralez.com.
For further information: please visit www.aralez.com.
Photo courtesy of Aralez Pharmaceuticals Inc